Abstract:Autoimmune liver diseases (AILD) include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). These immune-mediated liver diseases involve a break down in peripheral self-tolerance with largely unknown aetiology. Regulatory T cells (Treg) are crucial in maintaining immunological tolerance. Hence, Treg immunotherapy is an attractive therapeutic option in AILD. Currently, AILD do not have a curative treatment option and patients take life-long immunosuppression or bile acids to control hepatic or biliary inflammation. Clinical investigations using good manufacturing practice (GMP) Treg in autoimmune liver disease have thus far demonstrated that Treg therapy is safe and that Treg migrate to inflamed liver tissue. For Treg immunotherapy to achieve efficacy in AILD, Treg must be retained within the liver and maintain their suppressive phenotype to dampen ongoing immune responses to hepatocytes and biliary epithelium. Therefore, therapeutic Treg subsets should be selected for tissue residency markers and maximal functionality. Optimisation of dosing regime and understanding longevity of Treg in vivo are critical to successful Treg therapy. It is also essential to consider combination therapy options to complement infused Treg, for instance low-dose interleukin-2 (IL-2) to support pre-existing and infused Treg survival and suppressive function. Understanding the hepatic microenvironment in both early- and late-stage AILD presents significant opportunity to better tailor Treg therapy in different patient groups. Modification of a hostile microenvironment to a more favourable one either prior to or during Treg therapy could enhance the efficacy and longevity of infused GMP-Treg. Applying recent technology to discovery of autoantigen responses in AILD, T cell receptor (TCR) sequencing and use of chimeric antigen receptor (CAR) technology represents the next frontier for disease-specific CAR-Treg therapies. Consideration of all these aspects in future trials and discovery research would position GMP Treg immunotherapy as a viable personalised-medicine treatment option for effective control of autoimmune liver diseases.

[The Immune-Modulation Therapy of Autoimmune Liver Diseases].

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Diagnosis and Treatment of Autoimmune Hepatic Disease

Unmet Challenges in Immune-Mediated Hepatobiliary Diseases

The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease

A HeLa cell clonal line lacking alkaline phosphatase activity.

Animal Models of Autoimmune Liver Diseases: a Comprehensive Review

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies

Clinical Analysis of 187 Patients with Autoimmune Liver Diseases

Autoimmune Biliary Diseases: A Review of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Immunoglobulin G4-Related Sclerosing Cholangitis, and Autoimmune Hepatitis

[Clinical use of helium-oxygen mixture revisited]

Complex Interplay Between the Immune System, Metabolism, and Epigenetic Factors in Autoimmune Liver Diseases

The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes

Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges

Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies

Interorgan communication with the liver: novel mechanisms and therapeutic targets

Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease

Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis